Mega Lifesciences PCL (BKK:MEGA)

Mega Lifesciences PCL Balance Sheet

Financials in millions THB. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,358	3,463	2,357	2,453	2,198	1,006
Short-Term Investments	350.06	395.19	365.05	345.55	342.64	225.85
Cash & Short-Term Investments	3,708	3,858	2,722	2,799	2,540	1,232
Cash Growth	0.40%	41.74%	-2.76%	10.18%	106.14%	-16.02%
Accounts Receivable	2,892	2,975	3,314	3,107	2,557	2,507
Other Receivables	307.71	152.53	158.28	180.15	164.18	74.68
Receivables	3,200	3,128	3,472	3,287	2,721	2,581
Inventory	3,029	3,033	3,377	4,109	3,823	3,489
Prepaid Expenses	-	60.43	58.59	60.14	53.43	43.95
Other Current Assets	171.84	147.7	360.23	334.95	162.8	240.19
Total Current Assets	10,110	10,227	9,990	10,590	9,301	7,587
Property, Plant & Equipment	2,406	2,213	2,225	2,151	2,103	2,214
Long-Term Investments	38.57	40.39	221.15	222.88	214.79	194.47
Goodwill	441.14	449	456.24	465.88	476.25	437.32
Other Intangible Assets	868.9	869.72	862.23	863.31	876.89	875
Long-Term Deferred Tax Assets	320.66	299.89	278.95	250.32	210.41	175.03
Other Long-Term Assets	127.91	111.52	81	103.49	89.75	74.27
Total Assets	14,313	14,210	14,115	14,646	13,272	11,557
Accounts Payable	1,708	1,685	1,925	2,793	2,527	2,048
Accrued Expenses	761.65	1,102	1,140	1,604	1,283	823.52
Short-Term Debt	444.39	287.58	76	229.18	168.18	499.49
Current Portion of Leases	60.45	63.83	43.78	82.96	56.21	36.67
Current Income Taxes Payable	189.76	145.54	108.45	204.18	185.86	160.73
Other Current Liabilities	769.54	630.65	1,133	624.44	633.02	660.61
Total Current Liabilities	3,934	3,914	4,427	5,538	4,853	4,229
Long-Term Leases	136	139.83	132.06	108.73	131.94	111.31
Long-Term Deferred Tax Liabilities	1.99	1.05	2.14	-	-	0.98
Other Long-Term Liabilities	-	-	-	-	-	0.33
Total Liabilities	4,366	4,333	4,813	5,870	5,247	4,578
Common Stock	435.94	435.94	435.94	435.94	435.94	435.94
Additional Paid-In Capital	2,305	2,305	2,305	2,305	2,305	2,305
Retained Earnings	7,973	7,830	7,210	6,655	5,766	4,752
Comprehensive Income & Other	-767.03	-693.31	-648.11	-618.9	-503.97	-534.41
Total Common Equity	9,946	9,877	9,302	8,777	8,003	6,958
Minority Interest	0.1	0.08	0.02	0.07	22.3	21.29
Shareholders' Equity	9,946	9,877	9,302	8,777	8,025	6,979
Total Liabilities & Equity	14,313	14,210	14,115	14,646	13,272	11,557
Total Debt	640.84	491.24	251.84	420.87	356.33	647.47
Net Cash (Debt)	3,068	3,367	2,470	2,378	2,184	584.84
Net Cash Growth	-6.49%	36.31%	3.86%	8.89%	273.44%	1.37%
Net Cash Per Share	3.50	3.86	2.83	2.73	2.50	0.67
Filing Date Shares Outstanding	868.71	871.87	871.87	871.87	871.87	871.87
Total Common Shares Outstanding	868.71	871.87	871.87	871.87	871.87	871.87
Working Capital	6,176	6,312	5,563	5,052	4,448	3,358
Book Value Per Share	11.45	11.33	10.67	10.07	9.18	7.98
Tangible Book Value	8,636	8,558	7,984	7,447	6,650	5,645
Tangible Book Value Per Share	9.94	9.82	9.16	8.54	7.63	6.47

Updated Feb 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.